ValiRx PLC Exercise of Warrants (3870X)

TIDMVAL

RNS Number : 3870X

ValiRx PLC

28 August 2020

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Exercise of Warrants

London, UK 28 August 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces it has received notification for the exercise of a warrant over 250,000 ordinary shares in the Company at an exercise price of 12.5 pence per share providing the Company with proceeds of GBP31,250 ("Warrant Exercise").

The Company has also received notifications for the exercise of warrants pursuant to the Fundraise Warrants announced on 4 May 2020 in relation to the fundraise at the time. The Company has received, in aggregate, exercise of warrants over 2,791,666 ordinary shares at an exercise price of 13 pence per share providing the Company with aggregate proceeds of GBP362,916. The Company has previously applied to list these shares as part of the block listing of 9,034,734 ordinary shares of 0.1 pence each in the Company (announced on 19 August 2020), which were admitted to trading on AIM on 24 August 2020.

Application will be made to the London Stock Exchange to admit the 250,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 3 September 2020. The new ordinary shares will rank pari passu with the existing ordinary shares.

For the purposes of the Disclosure and Transparency Rules, following the issue of shares detailed above as a result of the Warrant Exercise and the exercise of 2,791,666 warrants pursuant to the ValiRx plc Fundraise Warrants May 2020 block listing application announced on 19 August 2020, the enlarged issued share capital of the Company will comprise 57,104,039 ordinary shares of 0.1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

A Total Voting Rights announcement will be released by the Company on 1 September 2020.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information please contact:

 
 ValiRx plc                                           Tel: [phone] 
                                                                       2628 
                                                             www.valirx.com 
  Suzanne Dilly                                    [e-mail] 
 
   Cairn Financial Advisers LLP (Nominated             Tel: [phone] 
   Adviser)                                                            0880 
   Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
   Peterhouse Capital Limited (Sole Broker)            Tel: [phone] 
   Duncan Vasey / Lucy Williams / Eran Zucker                          0930 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCPRMPTMTBTBPM

(END) Dow Jones Newswires

August 28, 2020 02:00 ET (06:00 GMT)